Agios Pharmaceuticals AGIO Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Agios Pharmaceuticals (AGIO) reported accretion (amortization) of discounts and premiums, investments of $1.14M in Q1 2026.
- How has Agios Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Agios Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 15.1% year-over-year, from $1.35M to $1.14M.
- What is the long-term trend for Agios Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2021 to 2025), Agios Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 1.2% compound annual growth rate (CAGR), from -$6.95M to $7.2M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or the accretion of discounts on debt securities held as investments. It reflects the gradual alignment of the purchase price of a security with its face value over the holding period. Investors use this to understand the non-cash components impacting the reported yield on the company's investment portfolio.